| Perico, Norberto |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Completed | N/A | 21 | Europe | Blood sampling | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 11/24 | 11/24 | | |
| Rambaldi, Alessandro |
| Active, not recruiting | 3 | 430 | Europe, Canada, US, RoW | Pelabresib, Ruxolitinib, Placebo | Constellation Pharmaceuticals | Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | 08/23 | 12/27 | | |
|
|
|
|
|
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 01/26 | 01/26 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Recruiting | 3 | 236 | Europe | Ponatinib + Blinatumomab, Chemotherapy + Imatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), ALL, Adult, Philadelphia-Positive ALL | 09/27 | 09/27 | | |
| Recruiting | 2a | 76 | Europe | Inotuzumab Ozogamicin (IO) | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia | 11/22 | 11/22 | | |
| Recruiting | 2 | 160 | Europe | Nivolumab 10 MG/ML | Medical University of Gdansk, Medical Research Agency | Hodgkin Lymphoma | 09/22 | 07/26 | | |
NCT04232241: Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia |
|
|
| Recruiting | 2 | 440 | Europe, RoW | Allogeneic Stem Cell Transplantation | Universitätsklinikum Hamburg-Eppendorf, DKMS Stiftung Leben Spenden, Clinical Trial Center North (CTC North GmbH & Co. KG) | Acute Myeloid Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes | 11/22 | 11/24 | | |
| Active, not recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
| Terminated | 2 | 25 | Europe | tagraxofusp | Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia | 01/24 | 01/24 | | |
| Active, not recruiting | 2 | 149 | Europe | Chemotherapy + Blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoid Leukemia, Philadelphia Chromosome-Negative B-Cell Precursor | 02/24 | 02/24 | | |
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Active, not recruiting | 2 | 90 | Europe | givinostat, givinostat (ITF2357) | Italfarmaco | Chronic Myeloproliferative Neoplasms | 12/26 | 12/26 | | |
| Active, not recruiting | 2 | 28 | Europe | Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet | Niguarda Hospital | CLL Transformation | 09/26 | 12/26 | | |
Haplo-CIK, NCT03821519: Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant |
|
|
| Recruiting | 1/2 | 20 | Europe | donor-derived CIK cells | A.O. Ospedale Papa Giovanni XXIII | Relapsed Hematologic Malignancy | 05/22 | 05/23 | | |
| Terminated | 1/2 | 63 | Europe | NMS-03592088 | Nerviano Medical Sciences | Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML) | 08/24 | 08/24 | | |
NCT05869279: Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1/2 | 29 | Europe | CARCIK-CD19 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | B-cell NHL, CLL | 09/26 | 09/27 | | |
BET2017, NCT03823365: Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia |
|
|
| Active, not recruiting | 1 | 19 | Europe | Blinatumomab Expanded T-cells (BET) | A.O. Ospedale Papa Giovanni XXIII | Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia | 11/21 | 11/22 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Recruiting | N/A | 552 | Europe, US, RoW | | Fondazione per la Ricerca Ospedale Maggiore, European Leukemia Net | Myeloproliferative Neoplasm, COVID | 02/22 | 08/22 | | |
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
|
|
| Recruiting | N/A | 319 | Europe | Ropeginterferon alfa-2b, Besremi | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Polycythemia Vera | 09/26 | 12/26 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia |
|
|
| Recruiting | N/A | 60 | Europe | Dasatinib and blinatumomab | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Lymphoblastic Leukemia | 05/24 | 05/24 | | |
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL |
|
|
| Recruiting | N/A | 32 | Europe | bone marrow and/or peripheral blood samples withdrawal | Gruppo Italiano Malattie EMatologiche dell'Adulto | T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All | 05/24 | 05/24 | | |
| Recruiting | N/A | 617 | Europe, RoW | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline | Myelofibrosis | 12/25 | 12/28 | | |
| Not yet recruiting | N/A | 100 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | VEXAS | 02/25 | 06/25 | | |
| Recruiting | N/A | 6000 | Europe | Patient registry | A.O. Ospedale Papa Giovanni XXIII | Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma | 03/27 | 03/37 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma |
|
|
| Recruiting | N/A | 300 | Europe, US, RoW | | International Extranodal Lymphoma Study Group (IELSG) | Nodal Marginal Zone Lymphoma | 12/26 | 12/26 | | |
| Remuzzi, Giuseppe |
| Terminated | 3 | 2 | Europe | Veltassa Oral Powder Product, Placebo | Mario Negri Institute for Pharmacological Research, Vifor Pharma | Hyperkalemia | 11/24 | 11/24 | | |
| Completed | 2 | 32 | Europe | Dapagliflozin 10Mg Tab, Placebo | Mario Negri Institute for Pharmacological Research, AstraZeneca | Chronic Kidney Diseases | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 10 | Europe | MOR202, FELZARTAMAB | Mario Negri Institute for Pharmacological Research, MorphoSys AG | Membranous Nephropathy | 02/25 | 02/25 | | |
| Terminated | 1/2 | 29 | Europe | Mesenchymal Stromal Cells, Allogeneic Cellular Therapy (NEPHSTROM ORBCEL-M), Placebo, Cryostor CS10 | Mario Negri Institute for Pharmacological Research, Leiden University Medical Center, Papa Giovanni XXIII Hospital, Istituto Di Ricerche Farmacologiche Mario Negri, Belfast Health and Social Care Trust, National University of Ireland, Galway, Ireland, University Hospital Birmingham, NHS Foundation Trust, Hospital, Birmingham, UK, NHS Blood and Transplant | Diabetic Kidney Disease | 11/22 | 01/24 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Recruiting | N/A | 140 | Europe | Non- contrast Enhanced Multiparametric Renal Magnetic Resonance | Mario Negri Institute for Pharmacological Research, Clinica Universidad de Navarra, Universidad de Navarra, Aarhus University Hospital, Heidelberg University | Chronic Kidney Diseases, Healthy | 12/24 | 12/24 | | |
| Recruiting | N/A | 70 | Europe | Octreotide, Octreotide LAR | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney | 12/24 | 12/24 | | |
| Recruiting | N/A | 75 | Europe | RATG, Thymoglobulin, Basiliximab, Simulect | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 09/25 | 09/25 | | |
AI4PKD, NCT06688981: Artificial Intelligence-based Image Processing Methods to Advance the Characterization of Polycystic Kidney Disease |
|
|
| Active, not recruiting | N/A | 100 | Europe | | Mario Negri Institute for Pharmacological Research | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 10/34 | 10/34 | | |
| Recruiting | N/A | 10 | Europe | PerSorb cartridge (CytoSorbents Europe GmbH, Germany), PerLife PerKidney | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 05/26 | 05/26 | | |
AI-TIME, NCT06690190: Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs |
|
|
| Active, not recruiting | N/A | 100 | Europe | | Mario Negri Institute for Pharmacological Research | End-Stage Renal Disease | 11/34 | 11/34 | | |
| Not yet recruiting | N/A | 100 | Europe | In-house ELISA, and ELISA kits from "DBA Italy" (Abbexa). | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 05/28 | 05/28 | | |
| Not yet recruiting | N/A | 500 | Europe | | Mario Negri Institute for Pharmacological Research | Membranous Nephropathy | 12/29 | 12/29 | | |
Cy-STEM, NCT06797609: Comparing the Performance of Serum Creatinine and Cystatin C-based GFR Estimations in Predicting Directly Measured GFR in Patients With or Without Nephrotic Syndrome |
|
|
| Not yet recruiting | N/A | 50 | Europe | Sample analyses | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 03/26 | 03/26 | | |
| Completed | N/A | 21 | Europe | Blood sampling | Mario Negri Institute for Pharmacological Research | Nephrotic Syndrome | 11/24 | 11/24 | | |
| Introna, Martino |
Haplo-CIK, NCT03821519: Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant |
|
|
| Recruiting | 1/2 | 20 | Europe | donor-derived CIK cells | A.O. Ospedale Papa Giovanni XXIII | Relapsed Hematologic Malignancy | 05/22 | 05/23 | | |
NCT02012153: Mesenchymal Stromal Cells in Kidney Transplant Recipients |
|
|
| Terminated | 1 | 3 | Europe | Mesenchymal Stromal Cells | Mario Negri Institute for Pharmacological Research, A.O. Ospedale Papa Giovanni XXIII | Kidney Transplant Rejection | 05/23 | 05/23 | | |
| Recruiting | 1 | 20 | Europe | Mesenchymal Stromal Cells | Monia Lorini, Mario Negri Institute for Pharmacological Research | Liver Transplant Rejection | 10/24 | 10/25 | | |
| Tondini, Carlo |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
| Active, not recruiting | 2 | 400 | Europe | Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib | Fondazione per la Medicina Personalizzata | Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer | 12/24 | 06/25 | | |
MAGNETIC1, NCT05814224: Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA |
|
|
| Recruiting | N/A | 164 | Europe | Liquid biopsy and CT scan | Centro di Riferimento Oncologico - Aviano | Hormone Receptor Positive Breast Carcinoma, Breast Neoplasms, Neoplasms, Breast, Breast Diseases, Antineoplastic Agents, Aromatase Inhibitors, ESR1 Gene Mutation | 12/23 | 12/24 | | |
| Recruiting | N/A | 3000 | Europe | | Federation of Italian Cooperative Oncology Groups, Roche Pharma AG, AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, LP, Takeda, Amgen, Daiichi Sankyo, Inc., Eli Lilly and Company, Novartis, Clinical Research Technology S.r.l. | Solid Tumours in Advanced Stages | 10/26 | 10/26 | | |
